Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 1997

View Archived Issues

SciClone awarded grant for clinical development of cystic fibrosis therapy

Quidel and Glaxo Wellcome sign agreement for diagnostic tests

TheraTech joins forces with Meiji and Sankyo to develop and market oxybutynin patch

Nastech files IND for new formulation of buprenorphine

Spotlight on angiotensin II blocker/ACE inhibitor combination therapy

Patent issued for Fluorovent technology

FDA approval granted for Carbatrol

Hoechst discloses antiischemic agents

Novel neural antiapoptotic polypeptide discovered by Novartis

Aviron updates vaccine clinical program

BMS and ICAgen establish ion channel collaboration

Vanguard licenses VML-252 to Sankyo

Phase II results for ganaxolone in epilepsy and migraine anticipated by year-end

PathoGenesis receives grant for new antibiotic for CF infections

Scios/Wyeth-Ayerst commence large pivotal trials of bFGF for stroke

New immunotherapy for metastatic tumors reported

Selective iNOS inhibitor inhibits tumor growth in mice

Collagen to spin off two companies

Progress made on MMAC-1 research; Schering-Plough acquires rights to therapies

Renal effects of NO donor FK-409 in dogs

Demeter BioTechnologies awarded grant for cancer therapeutics program

VA-045 effective against TBI-induced retrograde and anterograde amnesia

ImmuCell receives grant to develop TravelGAM

DUROS leuprolide enters phase III for prostate cancer

Cubist and Merck expand antibiotic collaboration

Important NRC discovery related to stroke and epilepsy

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026